Exicure Strengthens Position with $10M Investment and Corporate Restructuring

Exicure Strengthens Its Position with Strategic Investment and Corporate Restructuring

Exicure, Inc., a biotechnology company specializing in nucleic acid therapies, is poised for a significant transformation following a recently approved change of control transaction by its stockholders. This transaction includes a substantial investment of $8.7 million from HiTron Systems Inc., a publicly listed South Korean company. Once finalized, HiTron’s total investment in Exicure will reach $10 million, positioning it as the largest shareholder with over 50% ownership. This new influx of capital not only bolsters Exicure’s financial standing but also signals a renewed focus on its core therapeutic pipeline, allowing the company to explore further strategic opportunities in the biotechnology sector.

As part of this transition, Exicure has expanded its Board of Directors to nine members, introducing four new directors and two officers. This restructuring is aimed at enhancing governance and strategic direction, aligning the company’s leadership with its renewed focus on nucleic acid therapies. The recent investments are expected to provide the necessary resources for Exicure to address its operational challenges and leverage potential collaborations, including ongoing discussions with a U.S. therapeutics company. By enhancing its leadership team and increasing its financial backing, Exicure positions itself to navigate the complexities of the biotechnology landscape more effectively.

In addition to securing investments, Exicure has entered into a Common Stock Purchase Agreement with SangSangIn Investment & Securities Co., Ltd., agreeing to issue 433,332 shares at $4.61 per share, generating approximately $2 million in net proceeds. These capital injections come at a crucial time as Exicure deals with a notification from Nasdaq regarding non-compliance with the minimum stockholders’ equity requirement. The company has submitted a plan to a Nasdaq Hearings Panel to regain compliance, which is supported by the recent financial investments. Exicure’s ability to meet Nasdaq’s listing requirements while restructuring its operations will be vital for its future growth and market presence.

Exicure's recent moves reflect a strategic pivot aimed at reinforcing its operational capabilities in a competitive biotechnology market. With a clear focus on nucleic acid therapies and a strengthened board, Exicure is setting the stage for potential growth and innovation in the therapeutic landscape.